Core Viewpoint - The article highlights the successful IPO of Bokan Vision Pharmaceutical Co., Ltd., which is positioned to become a leader in the ophthalmic biotechnology sector with innovative drug candidates like CBT-001 and CBT-009 aimed at addressing unmet medical needs in eye diseases [3][5][9]. Company Overview - Bokan Vision is a biotechnology company focused on developing differentiated drugs for major eye diseases using proprietary technology platforms, including small molecule multi-kinase inhibitors and antibody-drug conjugates [6]. - The company has launched two key drug candidates: CBT-001 for treating pterygium and CBT-004 for treating vascularized eyelid lesions, both of which are expected to be the first of their kind globally [6][9]. IPO Details - On July 3, Bokan Vision officially listed on the Hong Kong Stock Exchange under the stock code "2592," raising approximately HKD 522 million through the issuance of 60.582 million shares, with a public offering oversubscribed by 78.78 times [3][4]. - The company attracted two cornerstone investors, raising a total of USD 22.8 million (approximately HKD 179 million) [3]. Clinical Development - CBT-001 has initiated Phase III clinical trials in the U.S. and China, with the potential to provide non-invasive treatment options for pterygium, thereby reducing the need for surgical intervention [8][9]. - CBT-009, aimed at treating myopia in adolescents, completed Phase I/II trials and is set to submit an IND application to the FDA in July 2024 [8][9]. Market Potential - The ophthalmic drug market is projected to exceed USD 10 billion in China, indicating significant growth potential in the sector [9]. - The demand for new ophthalmic drugs is increasing due to slow development progress in the field, making it a promising area for investment and innovation [9].

Performance Overview - In 2024, the company achieved revenue of CNY 1.943 billion, a year-on-year increase of 32.42% [2] - The total profit for 2024 was CNY 395 million, up 49.07% from the previous year [2] - The net profit attributable to shareholders was CNY 338 million, reflecting a growth of 40.84% [3] - In Q1 2025, revenue reached CNY 536 million, a 53.24% increase year-on-year [3] - The total profit for Q1 2025 was CNY 178 million, showing a remarkable growth of 277.02% [3] - The net profit attributable to shareholders in Q1 2025 was CNY 146 million, up 319.86% [3] Dividend Policy - The proposed dividend for 2024 is CNY 10 per 10 shares, with a bonus issue of 4 shares for every 10 shares held [3] Product and Market Strategy - The company focuses on self-research and development, enhancing core competitive advantages, and optimizing customer structure [2] - The product "Meioupin®" (0.01% atropine sulfate eye drops) accounted for over 10% of the company's main business revenue in 2024 [4] - The company has established a comprehensive sales network covering both online and offline channels, enhancing accessibility for consumers [5] - Collaborations with over 200 chain pharmacies and more than 12,000 outlets have been established to meet diverse patient needs [5] Market Potential and Growth - The overall myopia rate among children and adolescents in China is 52.7%, with significant market potential for myopia prevention products [10] - The company aims to raise awareness of the treatment plan to over 20 million people and ensure over 1 million children receive proper medication [10] - The company plans to maintain a double-digit growth rate in 2025, with a focus on optimizing cost control and improving operational efficiency [12] Sales and Distribution Channels - The company has entered over 4,000 public and private medical institutions, with plans for further expansion [11] - The sales strategy includes a full-channel marketing approach, integrating hospitals, pharmacies, and e-commerce platforms [9] - In 2024, offline channels accounted for over 50% of atropine sales [9] Future Outlook - The company anticipates stable growth in net profit margins, projecting a net profit margin of 25%-30% as atropine sales increase [16] - Continuous investment in R&D for innovative ophthalmic drugs is planned to enhance competitive advantage [17] - The company is preparing for potential overseas market expansion, leveraging its differentiated product pipeline [16]